BioPharm International - October 2021

BioPharm-October 2021-Regulatory-Sourcebook

Issue link: https://www.e-digitaleditions.com/i/1420307

Contents of this Issue

Navigation

Page 8 of 33

www.biopharminternational.com October 2021 eBook BioPharm International 9 stakeholders of the supply chain. • "Traceability of medical products is an important aspect of supply chain integrity. • "Effective and well-resourced national health regulator y authorities are essential to secure national and global regulated supply chains. • "It is crucial that national authorities are given appropriate powers to enforce reg ulations on the good distribution practice of medica l products. • "Customs authorities must also be trained and made aware of the issue of SF [substandard and falsif ied] m e d ic a l p r o d u c t s a n d s h o u l d establish and maintain effective lines of communication and information sha r ing w it h med ica l produc ts regulatory authorities." To address the issue of substan- dard and falsif ied medical products, WHO has used the following approach since 2012: • W HO Globa l Sur veil lance and M o n it o r i n g S y s t e m (G S M S) : C ou nt r ie s re p or t i nc ident s of substandard and falsif ied medical products into a database. After which time, WHO's technical staff provide assistance. According to WHO, this is the basis for structuring evidence- based policies and deploying projects. • Memb er St ate Me c h a n ism on Substandard and Falsified Medical Products: To facilitate political support for operational initiatives, members identify major needs and work with technical experts to fill the gaps in this intergovernmental process. " T hrough the GSMS, we have reports from multiple countries regard- ing the distribution for sale of falsi- fied COVID-19 vaccines," said WHO. "The hoarding of certain therapeutics is also a concern for us because con- strained access (for example, due to shortages) is a known driver of SF [sub- standard and falsified] medical prod- ucts. We regularly communicate both to the general public and specific target audiences (national regulatory authori- ties) on confirmed SF medical products, identified threats, or watch lists." Substandard and falsified COVID- 19 vaccines may not cause harm imme- diately. In some cases, it may simply lead to a false sense of safety. But over time and with enough incidences, these illicit products could lead to a lack of faith in the vaccine's effectiveness. The only stop to the pandemic is either herd immunity or more of the world's population having access to legitimate vaccines—and tak- ing it. Therefore, a secure global supply chain is more important now than ever. REFERENCES 1. H. Ritchie, et. al. "Coronavirus (COVID-19) Vaccinations," Our World Data, www.ourworldindata.org/covid- vaccinations?country=USA, accessed August 12, 2021. 2. ResearchAndMarkets, "Coronavirus Disease 2019 (COVID-19) Vaccines— Opportunity Assessment and Forecast to 2026," www.researchandmarkets.com/ reports/5360021/coronavirus-disease-2019- covid-19-vaccines, June 2021. 3. Medicine Quality Research Group, Centre of Tropical Medicine & Global Health, Nuffield Department of Medicine, University of Oxford, Medical Product Quality Report– COVID-19 Vaccine Issues, p. 4, 7, April 16, 2021. 4. J. Hopkins, J. de Córdoba, "Pfizer Identifies Fake Covid-19 Shots Abroad as Criminals Exploit Vaccine Demand," The Wall Street Journal, April 21, 2021. 5. S. Gupta, J. Yeung, "Thousands Thought They Were Getting the Covid Vaccine. They Were Injected with Salt Water Instead," CNN, July 5, 2021. 6. A. Wexler, "Fake Covid-19 Vaccines Pose New Threat in Africa," The Wall Street Journal, June 6, 2021. 7. FDA, "Counterfeit Medicine," www.fda. gov/drugs/buying-using-medicine-safely/ counterfeit-medicine, accessed 08/12/2021. 8. WHO, "A Study on the Public Health and Socioeconomic Impact of Substandard and Falsified Medical Products," WHO.int, www.who.int/ medicines/regulation/ssffc/publications/ SE_Study_EN.pdf, 2017. 9. WHO, "The WHO Member State Mechanism on Substandard and Falsified Medical Products," WHO.int, www. who.int/publications/i/item/WHO-MVP- EMP-SAV-2019.04, June 24, 2020.BP Regulatory Sourcebook Drug Safety While some counterfeit drug products are almost identical visually to the original drug product, here are some of the World Health Organization's (WHO's) key considerations (1): • Look at the condition of the package • Look for spelling or grammatical mistakes • Check if the manufacturing and expiration dates on the outer packaging match the inner packaging • See if it's discolored, smells unusual, etc. • Exercise caution when purchasing drug products from unregulated websites. • However, if vaccines are supplied through the standard—and reg- ulated—supply chains, WHO states there is a low risk of falsif ied vaccines (2). References 1. W H O, " Su b s t a n d a r d a n d Fa ls i f i e d M e d i c a l Pr o d u c t s ," W H O. i nt , www.who.int/news-room/fact-sheets/detail/substandard-and-falsi- fied-medical-products, Januar y 31, 2018. 2. Gavi, "How Can I Spot A Fake COVID -19 Vaccine?," Gavi.org, www. gavi.org/vaccineswork/how-can-i-spot-fake-covid-19-vaccine, July 2, 2021. Spotting Counterfeit COVID-19 Vaccines According to statistics released by WHO in 2017, there is a 10.5% failure rate of medicines in low- and middle-income countries.

Articles in this issue

Links on this page

Archives of this issue

view archives of BioPharm International - October 2021 - BioPharm-October 2021-Regulatory-Sourcebook